Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum
06 Julio 2023 - 6:00AM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a
clinical-stage biotechnology company developing innovative
therapies for the treatment of immune-mediated diseases, today
announced that Todd C. Brady, M.D., Ph.D., President and Chief
Executive Officer, will participate in the SVB Securities
Therapeutics Forum. The Forum will be held July 11-12, 2023, in New
York City.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to
discovering innovative therapies designed to treat immune-mediated
diseases. Our approach is to develop pharmaceuticals that modulate
immunological systems, instead of directly inhibiting or activating
single protein targets, with the goal of optimizing multiple
pathways at once while minimizing toxicity. Our product candidates
include RASP (reactive aldehyde species) modulators ADX‑629,
ADX‑246, ADX‑248, and chemically related molecules for the
potential treatment of systemic and retinal immune-mediated
diseases. Our pre-commercial product candidates are reproxalap, a
RASP modulator for the potential treatment of dry eye disease
(under U.S. Food and Drug Administration New Drug Application
Review) and allergic conjunctivitis, and ADX-2191, a novel
formulation of intravitreal methotrexate for the potential
treatment of proliferative vitreoretinopathy and retinitis
pigmentosa.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230706700451/en/
Investor & Media Contact: David Burke Tel: (917)
618-2651 investorrelations@aldeyra.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024